logo
Plus   Neg
Share
Email

6 Top Gainers In Pharma Sector (ABIO, PRPO, VCYT...)

pharmaup-may01-lt.jpg

The following are some of today's top gainers in the pharma/biotech sector.

1. ARCA biopharma Inc. (ABIO)

ARCA biopharma is a clinical-stage biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.

The Company's lead product candidate is Gencaro, which is in the development for the treatment of atrial fibrillation in certain patients who also have heart failure (HF). Gencaro is all set to advance into a phase III trial, dubbed PRECISION-AF, in the fourth quarter of this year.

Gained 98.64% to close Wednesday's (May 1) trading at $10.25.

News: The Company announced that the results of its phase IIb trial, which compared the effectiveness of Gencaro (bucindolol) against active control metoprolol succinate (TOPROL-XL) for the maintenance of sinus rhythm in a genetically-defined heart failure population with atrial fibrillation, dubbed GENETIC-AF, are published in the Journal of American College of Cardiology: Heart Failure.

The lead author of the paper Jonathan Piccini concluded that although Gencaro did not reduce the recurrence of atrial fibrillation (AF), atrial flutter (AFL) or all-cause mortality (ACM) compared to metoprolol, the majority of patients in the trial demonstrated a more favorable response to genetically-targeted Gencaro compared to standard beta-blocker therapy. Piccini added that the data are very encouraging and merit further investigation in future Phase 3 trials.

The results were reported by the Company on February 26, 2018, which sent the shares down nearly 72% to $8.10 that day.

2. Precipio Inc. (PRPO)

Precipio is a cancer diagnostics company.

Gained 38.84% to close Wednesday's trading at $8.40.

News: The Company announced that it will provide a corporate update on May 6, 2019.

Recent events:

-- On April 29, 2019, the Company signed a services contract with a health care management group serving several major hospitals based in Cairo, Egypt. The contract is expected to generate over $1.5 million in revenues annually for Precipio.

-- In order to regain compliance with the Nasdaq minimum bid price requirement of $1.00, Precipio implemented a 1-for-15 reverse stock split on April 26, 2019, and its shares began trading on a split-adjusted basis at the open of business on Monday, April 29, 2019.

3. Pacira Pharmaceuticals Inc. (PCRX)

Pacira BioSciences provides non-opioid pain management and regenerative health solutions for health care practitioners and their patients in the United States. The Company's lead marketed product is Exparel, a long-acting non-opioid pain drug.

Gained 16.15% to close Wednesday's trading at $46.25.

News: Pacira's competitor Heron Therapeutics Inc. (HRTX) has been issued a Complete Response Letter for its pain drug candidate HTX-011. The FDA has sought additional Chemistry and Manufacturing Controls (CMC), and non-clinical information related to HTX-011 from Heron.

4. CohBar Inc. (CWBR)

CohBar is a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases.

Gained 13.06% to close Wednesday's trading at $2.77.

News: No news

Near-term Catalyst:

The company is slated to report its first quarter 2019 financial results and will provide an update on its business on May 7, 2019.

5. ReWalk Robotics Ltd. (RWLK)

Rewalk manufactures and markets wearable robotic exoskeletons for individuals with lower limb disabilities as a result of spinal cord injury or stroke.

Gained 12.17% to close Wednesday's trading at $3.87.

News: No news

Recent events:

-- On April 26, 2019, the Company regained compliance with Nasdaq Listing Rules related to the minimum $35 million market value of listed securities requirement and $2.5 million shareholders' equity and $500,000 net income standards.

-- On February 8, 2019, the Company reported financial results for the fourth quarter and full-year ended December 31, 2018. Total revenue for the fourth quarter of 2018 was $1.6 million compared to $1.5 million in the prior year quarter.

Near-term Catalyst:

-- The Company is scheduled to release its first quarter 2019 financial results next week (May 10 - May 14).

6. Veracyte Inc. (VCYT)

Veracyte is a commercial-stage genomic diagnostics company.

Gained 10.06% to close Wednesday's trading at $25.17.

News: The Company reported a narrower loss on 27% revenue growth, and boosted its 2019 annual revenue guidance.

Net loss narrowed to $1.92 million or $0.05 per share on revenue of $29.53 million. This compared with a net loss of $9.2 million or $0.27 per share and revenue of $20 million in the year-ago quarter.

For 2019, the Company now expects annual revenue to be in the range of $117 million to $121 million from its prior guidance range of $113 million to $117 million.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT
>